Stockreport

Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma [Yahoo! Finance]

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF MARSEILLE, France, March 06, 2024 BUSINESS WIRE )--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (" Innate " or the " Company ") today announc [Read more]